Last reviewed · How we verify
HBM4003 and pembrolizumab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HBM4003 and pembrolizumab (HBM4003 and pembrolizumab) — Harbour BioMed (Guangzhou) Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HBM4003 and pembrolizumab TARGET | HBM4003 and pembrolizumab | Harbour BioMed (Guangzhou) Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HBM4003 and pembrolizumab CI watch — RSS
- HBM4003 and pembrolizumab CI watch — Atom
- HBM4003 and pembrolizumab CI watch — JSON
- HBM4003 and pembrolizumab alone — RSS
Cite this brief
Drug Landscape (2026). HBM4003 and pembrolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/hbm4003-and-pembrolizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab